KDNY Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Chinook Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
KDNY Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Chinook Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
- -3.42
- -3,211.95%
- -4,199.93%
- 0%
About KDNY
- Founded
- n/a
- Employees
- 214
- CEO
- WebsiteView website
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
